PDF herunterladen
Exp Clin Endocrinol Diabetes 2004; 112(9): 493-503
DOI: 10.1055/s-2004-821306
Review

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Global Risk Management in Type 2 Diabetes: Blood Glucose, Blood Pressure, and Lipids - Update on the Background of the Current Guidelines

A. Clemens1 , E. Siegel2 , B. Gallwitz3
  • 1Hübschstrasse 16, Karlsruhe, Germany
  • 2St.-Vincenz-Krankenhaus, Limburg, Germany
  • 3Medizinische Universitätsklinik der Eberhard-Karls-Universität Tübingen, Abt. Innere Medizin IV, Tübingen, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. Oktober 2004 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Diabetes mellitus presents a significant public health burden based on its increased morbidity, mortality, and economic cost. The high comorbidity and prevalence of concomitant diseases like hypertension and dyslipidemia in diabetic patients cause the high risk in developing secondary, cost intensive, and for the patient often disastrous late complications (nephropathy, retinopathy, neuropathy, and cardiovascular disease). Therefore, patients with diabetes mellitus need a global risk management that takes the various individual clinical problems into account. The current global standards of therapy in patients with diabetes mellitus are focused on the control of glycemia, blood pressure, and lipid levels, as well as aspirin therapy and avoiding of smoking. There are a number of guidelines and recommendations to manage these global issues. Our review will summarize current recommendations and consolidate therapeutic goals and treatments that are of vital importance in the global risk management in diabetic patients.

Key words

Type 2 diabetes mellitus - hypertension - dyslipidemia - diabetes guidelines - cardiovascular risk management

References

  • 1 Adler A I, Stratton I M, Neil H AW, Yudkin J S, Matthews D R, Cull C A, Wright A D, Turner R C, Holman R R. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.  BMJ. 2000;  321 412-419
    CrossrefPubMedGoogle Scholar
  • 2 Alberti G. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1998 - 1999 International Diabetes Federation European Region.  Exp Clin Endocrinol Diabetes. 1999;  107 390-420
    PubMedGoogle Scholar
  • 3 Alvarsson M, Steen L, Sundkvist G, Westermark G, Lager I, Westermark P, Henricsson M, Örn T, Berntrop K, Grill V, Fernquist-Forbes E. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients.  Diabet Care. 2003;  26 2231-2237
    PubMedGoogle Scholar
  • 4 American Diabetes Association . Aspirin therapy in diabetes (Position statement).  Diabet Care. 2003;  26 S87-S88
    PubMedGoogle Scholar
  • 5 American Diabetes Association . Aspirin therapy in diabetes.  Diabet Care. 2000;  23 S61-S62
    PubMedGoogle Scholar
  • 6 American Diabetes Association . Diabetes management in correctional institutions.  Diabet Care. 2004 a;  27 S114-S121
    PubMedGoogle Scholar
  • 7 American Diabetes Association . Hypertension management in adults with diabetes.  Diabet Care. 2004 b;  27 S65-S67
    PubMedGoogle Scholar
  • 8 American Diabetes Association . Management of dyslipidemia in adults with diabetes.  Diabet Care. 2002;  25 S74-S77
    PubMedGoogle Scholar
  • 9 Armitage J. Lipid-lowering trails in diabetes.  Eur Heart J. 1999;  1 M13-M17
    PubMedGoogle Scholar
  • 96 Arauz-Pacheco C, Parrot M A. The treatment of hypertension in adult patients with diabetes.  Diabetes Care. 2002;  25 134-147
    CrossrefPubMedGoogle Scholar
  • 10 Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus.  Ann Intern Med. 1999;  131 182-188
    PubMedGoogle Scholar
  • 11 Bakris G L, Williams M, Dworkin L, Elliott W J, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.  Am J Kidney Dis. 2000;  36 646-661
    CrossrefPubMedGoogle Scholar
  • 12 Brand F N, Kannel W B, Evans J, Larson M G, Wolf P A. Glucose intolerance, physical signs of peripheral artery disease, and risk of cardiovascular events: the Framingham Study.  Am Heart J. 1998;  136 919-927
    PubMedGoogle Scholar
  • 13 Brandle M, Davidson M B, Schriger D L, Lorber B, Herman W H. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.  Diabet Care. 2003;  26 1796-1801
    PubMedGoogle Scholar
  • 14 Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L. World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee.  Clin Exp Hypertens. 1999;  21 1009-1060
    PubMedGoogle Scholar
  • 15 Chobanian A V, Bakris G L, Black H R, Cushman W C, Green L A, Izzo J L, Jones D W, Materson B J, Oparil S, Wright J T, Roccella E J. and the National High Blood Pressure Education Programm Coordinating Committee . The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report.  JAMA. 2003;  289 2560-2572
    CrossrefPubMedGoogle Scholar
  • 16 Corpus R A, George P B, House J A, Dixon S R, Ajulin S C, Devlin W H, Timmis G C, Balasubramaniam M, O'Neill W W. Optimal glycemic control is associated with lower rate of target vessel revascularisation in treated type II diabetic patients undergoing elective percutaneous coronary intervention.  J Am Coll Cardiol. 2004;  43 8-14
    CrossrefPubMedGoogle Scholar
  • 17 Curb J D, Pressel S L, Cutler J A. et al . Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.  JAMA. 1996;  276 1886-1892
    CrossrefPubMedGoogle Scholar
  • 18 Deutsche Hochdruckliga. Deutsche Hypertonie Gesellschaft .Empfehlungen zur Hochdruckbehandlung. 16th ed. Heidelberg; Deutsche Hochdruckliga 2001
    Google Scholar
  • 19 Expert Panel on Detection . Executive Summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
    CrossrefPubMedGoogle Scholar
  • 20 Feingold K R, Grunfeld C, Pang M, Doerrler W, Krauss R M. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes.  Ateroscler Thromb. 1992;  12 1496-1502
    PubMedGoogle Scholar
  • 21 Folsom A R, Chambless L E, Duncan B B, Gilbert A C, Pankow J S. Prediction of coronary heart disease in middle-aged adults with diabetes.  Diabet Care. 2003;  26 2777-2784
    PubMedGoogle Scholar
  • 22 Fonseca V, Rosenstock J, Patwardhan, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized, controlled trail.  J Am Med Assoc. 2000;  283 1695-1702
    CrossrefPubMedGoogle Scholar
  • 23 Fuller J H, Head J. Blood pressure, proteinuria and their relationship with circulatory mortality: the WHO multinational study of vascular disease in diabetics.  Diabetes Metab. 1998;  15 273-277
    PubMedGoogle Scholar
  • 24 Gaede P, Vedel P, Larsen N, Jensen G VH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  348 383-393
    Google Scholar
  • 25 Gagne C, Bays H E, Weiss S R, Mata P, Quinto K, Melino M, Cho M, Musliner T A, Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterinemia.  Am J Cardiol. 2002;  90 1084-1091
    CrossrefPubMedGoogle Scholar
  • 26 Gentile S, Turco S, Guarino G, Sasso C F, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R. Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterinemia.  Diabetes Obesity Metabol. 2000;  2 355-362
    PubMedGoogle Scholar
  • 27 Gohlke H, Kübler W, Mathes P, Meinertz T, Schuler G, Gysan D B, Sauer G. Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group.  Z Kardiol. 2001;  90 148-149
    PubMedGoogle Scholar
  • 28 Goldberg R B, Mellies M J, Sacks F M, Moye L A, Howard B V, Howard W J, Davis B R, Cole T G, Pfeffer M A, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.  Circulation. 1998;  98 2513-2519
    PubMedGoogle Scholar
  • 29 Greco A V, Mingrone G, Giancaterini A, Manco M, Morroni M, Cint S, Granzotto M, Vettor R, Camastra S, Ferrannini E. Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion.  Diabetes. 2002;  51 144-151
    PubMedGoogle Scholar
  • 30 Guidelines Committee . 2003 European society of hypertension - european society of cardiology guidelines for the management of arterial hypertension.  J Hypertens. 2003;  21 1011-1053
    CrossrefPubMedGoogle Scholar
  • 31 Haffner S M, Hanley A JG. Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects?.  Circulation. 2002;  105 2008-2009
    CrossrefPubMedGoogle Scholar
  • 32 Haffner S M, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. Implications for treatment of hyperlipidemia in diabetic subjects without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
    CrossrefPubMedGoogle Scholar
  • 33 Haller H. Posprandial glucose and vascular disease.  Diabetic Medicine. 1997;  14 S50-S56
    CrossrefPubMedGoogle Scholar
  • 34 Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.  Diabet Care. 1991;  14 308-317
    PubMedGoogle Scholar
  • 35 Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis.  Diabetic Medicine. 1999;  16 212-218
    CrossrefPubMedGoogle Scholar
  • 36 Hansson L, Zanchetti A, Carruthers S G, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn K H, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT). HOT Study Group.  Lancet. 1998;  351 1755-1762
    CrossrefPubMedGoogle Scholar
  • 37 Häring H-U, Joost H-G, Laube H, Matthaei S, Meissner H-P, Panten U, Schernthaner G. Evidenzbasierte Diabetes-Leitlinien DDG (Diskussionsentwurf). Antihyperglykämische Therapie des Diabetes mellitus Typ 2.  Diabetes und Stoffwechsel. 2001;  10 223-236
    PubMedGoogle Scholar
  • 38 Hauner H, Köster I, von Ferber L. Prävalenz des Diabetes mellitus in Deutschland 1998 - 2001.  Dtsch Med Wochenschr. 2003;  128 2632-2638
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 39 Heart Protection Study Collaborative Group . MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.  Lancet. 2003;  361 2005-2016
    CrossrefPubMedGoogle Scholar
  • 40 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
    CrossrefPubMedGoogle Scholar
  • 41 Heinemann L, Heise T. Klinische Wirkungen und Pharmakodynamik der Insulinanaloga Lispro, Aspart und Glargin.  Dtsch Med Wschr. 2001;  126 597-604
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 42 Hermann L S, Ranstam J, Vaaler, Melander A. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.  Diabetes Obes Metab. 1999;  1 227-232
    CrossrefPubMedGoogle Scholar
  • 43 Home P D, Boulton A JM, Jimenez J, Landgraf R, Osterbrink B, Christiansen J S. Issues relating to the early or earlier use of insulin in type 2 diabetes.  Pract Diab Int. 2003;  20 63-71
    CrossrefPubMedGoogle Scholar
  • 44 Hypertension in Diabetes Study Group . Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients.  J Hypertens. 1993;  11 319-325
    PubMedGoogle Scholar
  • 45 Janka H U, Standl E, Bloss G, Oberparleiter F, Mehnert H. On the epidemiology of hypertension in diabetics.  Dtsch Med Wochenschr. 1978;  103 84-87
    PubMedGoogle Scholar
  • 46 Jarrett R J, Shipley M J. The Whitehall Study: comparative mortality rates and indices of risk in diabetes.  Acta Endocrinol. 1985;  110 21-26
    PubMedGoogle Scholar
  • 47 Jeu L A, Cheng J WM. Pharmacology and therapeutics of ezetimibe (SCH 58 235), a cholesterol-absorption inhibitor.  Clin Ther. 2003;  25 2352-2387
    CrossrefPubMedGoogle Scholar
  • 48 Joint National Committee . The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Arch Intern Med. 1997;  157 2413-2443
    CrossrefPubMedGoogle Scholar
  • 49 Kalfhaus J, Berger M. Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study.  Diabetes & Metabolism. 2000;  26 197-201
    PubMedGoogle Scholar
  • 50 Kannel W B, McGee D L. Diabetes and cardiovascular risk factors in the framingham study.  Circulation. 1993;  59 8-13
    PubMedGoogle Scholar
  • 51 Keech A, Colquhoun D, Best J, Kirby A, Simes R J, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose.  Daibetes Care. 2003;  26 2713-2721
    PubMedGoogle Scholar
  • 52 Klocke K R, Stauch K, Landen H. Effect of add-on acarbose to insulin therapy in routine clinical practice.  Clin Drug Invest. 2003;  23 621-627
    PubMedGoogle Scholar
  • 53 Lefèbvre P J, Scheen A J. Glucose metabolism and the postprandial state.  Eur J Clin Invest. 1999;  29 1-6
    PubMedGoogle Scholar
  • 54 Lüscher T F, Creager M A, Beckman J A, Cosentino F. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part II.  Circulation. 2003;  108 1655-1661
    CrossrefPubMedGoogle Scholar
  • 55 Malmberg K, Norhammar A, Wedel H, Rydén L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction.  Circulation. 1999;  99 2626-2632
    CrossrefPubMedGoogle Scholar
  • 56 Manninen V, Tenkanen L, Koskinen P, Huttunen J K, Manttari M, Heinonen O P, Frick M H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.  Circulation. 1992;  85 37-45
    CrossrefPubMedGoogle Scholar
  • 57 Mathiesen E R, Borch-Johnsen K, Jensen D V, Deckert T. Improved survival in patients with diabetic nephropathy.  Diabetologia. 1989;  32 884-886
    CrossrefPubMedGoogle Scholar
  • 58 Menzel R, Kerner W, Meinecke G, Schmohl M. Typ-2-Diabetes: Insulintherapie kombiniert mit Metformin im Vergleich zur Insulinmonotherapie.  Diabetes und Stoffwechsel. 2002;  11 167-174
    PubMedGoogle Scholar
  • 59 Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner S M, Pyorala K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction.  Diabetes Care. 1998;  21 69-75
    PubMedGoogle Scholar
  • 60 Nathan D M. Long-term complications of diabetes mellitus.  N Engl J Med. 1993;  328 676-685
    PubMedGoogle Scholar
  • 61 Nationales Programm für Versorgungs-Leitlinien bei der Bundesärztekammer . Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2. Mai 2002; Kurzfassung.  Diabetes und Stoffwechsel. 2002;  11 185-205
    PubMedGoogle Scholar
  • 62 Oh J-Y, Barret-Connor E, Wedick N M. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults.  Circulation. 2002;  105 1311-1316
    CrossrefPubMedGoogle Scholar
  • 63 Parving H H, Hommel E. Prognosis in diabetic nephropathy.  BMJ. 1989;  229 230-233
    PubMedGoogle Scholar
  • 64 Practice Guidelines Writing Committee . Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines.  J Hypertens. 2003;  21 1011-1053
    CrossrefPubMedGoogle Scholar
  • 65 Pyorala K, Pedersen T R, Kjekshus J, Faergeman O, Olsson A G, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4 S).  Diabet Care. 1997;  20 614-620
    CrossrefPubMedGoogle Scholar
  • 66 Reaven P D, Barrett-Connor E L, Browner D K. Abnormal glucose tolerance and hypertension.  Diabet Care. 1990;  13 119-125
    PubMedGoogle Scholar
  • 67 Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study.  BMJ. 1989;  299 1127-1131
    PubMedGoogle Scholar
  • 68 Rubins H B, Robins S J, Collins D, Nelson D B, Elam M B, Schaefer E J, Faas F H, Anderson J W. Diabetes, plasma insulin, and cardiovascular disease.  Arch Intern Med. 2002;  162 2597-2604
    CrossrefPubMedGoogle Scholar
  • 69 Sacks F M, Pfeffer M A, Moye L A, Rouleau J L, Rutherford J D, Cole T G, Brown L, Warnica J W, Arnold J M, Wun C C, Davis B R, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.  N Eng J Med. 1996;  335 1001-1009
    CrossrefPubMedGoogle Scholar
  • 70 Sawicki P T, Mühlhauser I, Didjurgeit U. Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro- or macro-proteinuria.  Diabet Med. 1995;  12 893-898
    PubMedGoogle Scholar
  • 71 Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S).  Lancet. 1994;  344 1383-1389
    PubMedGoogle Scholar
  • 72 Schäfers R F, Lütkes P, Ritz E, Philipp T. Leitlinie zur Behandlung der arteriellen Hypertonie bei Diabetes mellitus.  DMW. 1999;  124 1356-1372
    PubMedGoogle Scholar
  • 97 Second joint task force of European and other societies on coronary heart disease in clinical practice .Recommendation of the second joint task force of European and other societies on coronary prevention Euro Heart. 
    Google Scholar
  • 73 Shaw J E, Hodge A M, de Courten M, Chitson P, Zimmet P Z. Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality.  Diabetologia. 1999;  42 1050-1054
    CrossrefPubMedGoogle Scholar
  • 74 Shek A, Ferill M J. Statin-fibrate combination therapy.  Ann Pharmacother. 2001;  35 908-917
    CrossrefPubMedGoogle Scholar
  • 75 Siegel E G, Jakobs R, Riemann J F. Pankreopriver und hepatogener Diabetes.  Internist. 2001;  42 S8-S19
    CrossrefPubMedGoogle Scholar
  • 76 Simonson D C. Etiology and prevalence of hypertension in diabetic patients.  Diabet Care. 1988;  11 821-827
    PubMedGoogle Scholar
  • 77 Snow V, Weiss K B, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus.  Ann Intern Med. 2003;  138 587-592
    PubMedGoogle Scholar
  • 78 Stamler J, Vaccaro O, Neaton J D, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial.  Diabet Care. 1993;  16 434-444
    CrossrefPubMedGoogle Scholar
  • 79 Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project.  Diabetologia. 1996;  39 1540-1545
    CrossrefPubMedGoogle Scholar
  • 80 Standl E, Fuchs C, Parandeh-Shab F, Janka U H, Landgraf R, Lengeling H-F, Phillip T, Petzoldt R, Sawicki P, Scherbaum W A, Tschöpe D. Hypertonie beim Diabetes Mellitus. In: Scherbaum WA, Landgraf R (eds). Praxisleitlinien der Deutschen Diabetes-Gesellschaft (DDG).  Diabetes und Stoffwechsel. 2002;  11 20-22
    PubMedGoogle Scholar
  • 81 Standl E, Fuchs C, Parandeh-Shab F, Janka U H, Landgraf R, Lengeling H-F, Phillip T, Petzoldt R, Sawicki P, Scherbaum W A, Tschöpe D. Management der Hypertonie beim Patienten mit Diabetes mellitus. Scherbaum WA, Lauterbach KW, Renner R Evidenzbasierte Diabetes-Leitlinien DDG. 1st ed. Deutsche Diabetes-Gesellschaft 2000
    Google Scholar
  • 82 Standl E, Stiegler H, Roth R, Schulz K, Lehmacher W. On the impact of hypertension on the prognosis of NIDDM. Results of the Schwabing GP-Program.  Diabetes Metab. 1989;  15 352-358
    PubMedGoogle Scholar
  • 83 Stratton I M, Adler A I, Neil H AW, Matthews D R, Manley S E, Cull C A, Hadden D, Turner R C, Holman R R. On behalf of the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type-2-diabetes (UKPDS 35): prospective observational study.  BMJ. 2000;  321 405-412
    CrossrefPubMedGoogle Scholar
  • 84 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic.  JAMA. 2002;  288 2981-2997
    CrossrefPubMedGoogle Scholar
  • 85 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Follow-up report on the diagnosis of diabetes mellitus.  Diabet Care. 2003;  11 3160-3167
    PubMedGoogle Scholar
  • 86 Tomigana M, Igarashi K, Eguchi H, Kato T, Manaka H, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose.  Diabet Care. 1999;  22 920-924
    PubMedGoogle Scholar
  • 87 Tuomilehto J, Rastenyte D, Birkenhager W H, Thijs L, Antikainen R, Bulpitt C J, Fletcher A E, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe trail investigators.  N Engl J Med. 1999;  340 677-684
    CrossrefPubMedGoogle Scholar
  • 88 Turner R C. The U. K. prospective diabetes study. A review.  Diabet Care. 1998;  21 C35-38
    PubMedGoogle Scholar
  • 89 UKPDS Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.  BMJ. 1998;  317 703-713
    PubMedGoogle Scholar
  • 90 Van den Berghe G, Wouters D, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients.  N Engl J Med. 2001;  345 1359-1367
    CrossrefPubMedGoogle Scholar
  • 91 West K M, Ahuja M M, Bennett P H, Czyzyk A, De Acosta O M, Fuller J H, Grab B, Grabauskas V, Jarrett R J, Kosaka K. The role of circulating glucose and triglyceride concentrations and their interactions with other “risk factors” as determinants of arterial disease in nine diabetic population samples from the WHO multinational study.  Diabet Care. 1983;  6 361-369
    CrossrefPubMedGoogle Scholar
  • 92 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.  Diabet Care. 2004;  27 1047-1054
    CrossrefPubMedGoogle Scholar
  • 93 Yudkin J S, May M, Elwood P, Yarnell J W, Greenwood R, Davey Smith G. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly study.  Diabetologia. 2002;  45 327-336
    CrossrefPubMedGoogle Scholar
  • 94 Zethelius B, Byberg L, Hales C N, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease.  Circulation. 2002;  105 2153-2158
    CrossrefPubMedGoogle Scholar
  • 95 Zimmet P Z, McCarty D J, De Courten M P. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome.  J Diabetes Complications. 1997;  11 60-68
    CrossrefPubMedGoogle Scholar

M. D. Andreas Clemens

Hübschstraße 16

76135 Karlsruhe

Germany

Telefon: + 49(0)7218304691

eMail: a_clemens@gmx.de

      >